Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study
Ashley Cimino‐Mathews, Xiaobu Ye, Alan K. Meeker, et al.
Human Pathology (2013) Vol. 44, Iss. 10, pp. 2055-2063
Open Access | Times Cited: 116

Showing 1-25 of 116 citing articles:

Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas, Roberto Salgado, Carsten Denkert, et al.
Nature Reviews Clinical Oncology (2015) Vol. 13, Iss. 4, pp. 228-241
Closed Access | Times Cited: 773
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors
Shona Hendry, Roberto Salgado, Thomas Gevaert, et al.
Advances in Anatomic Pathology (2017) Vol. 24, Iss. 6, pp. 311-335
Open Access | Times Cited: 667
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research
Shona Hendry, Roberto Salgado, Thomas Gevaert, et al.
Advances in Anatomic Pathology (2017) Vol. 24, Iss. 5, pp. 235-251
Open Access | Times Cited: 587
Immunotherapy and targeted therapy combinations in metastatic breast cancer
Francisco J. Esteva, Vanessa M. Hubbard-Lucey, Jun Tang, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 3, pp. e175-e186
Closed Access | Times Cited: 405
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
Ashley Cimino‐Mathews, Elizabeth D. Thompson, Janis M. Taube, et al.
Human Pathology (2015) Vol. 47, Iss. 1, pp. 52-63
Open Access | Times Cited: 314
Immunological differences between primary and metastatic breast cancer
Borbála Székely, Veerle Bossuyt, Xiaofeng Li, et al.
Annals of Oncology (2018) Vol. 29, Iss. 11, pp. 2232-2239
Open Access | Times Cited: 300
Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents
Matteo Santoni, Emanuela Romagnoli, Tiziana Saladino, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2017) Vol. 1869, Iss. 1, pp. 78-84
Closed Access | Times Cited: 199
Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples
Takayuki Iwamoto, Naoki Niikura, Rin Ogiya, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 190
The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes
Sayali Onkar, Neil Carleton, Peter C. Lucas, et al.
Cancer Discovery (2022) Vol. 13, Iss. 1, pp. 23-40
Open Access | Times Cited: 123
Triple-negative breast cancer metastasis involves complex epithelial-mesenchymal transition dynamics and requires vimentin
Eloïse M. Grasset, Matthew Dunworth, Gaurav Sharma, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 656
Open Access | Times Cited: 102
Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance
Tian‐Jian Yu, Gen‐Hong Di
Chinese Journal of Cancer Research (2017) Vol. 29, Iss. 3, pp. 237-252
Open Access | Times Cited: 146
Immune Targeting in Breast Cancer
Ashley Cimino‐Mathews, Jeremy B. Foote, Leisha A. Emens
Oncology (2015) Vol. 29, Iss. 5, pp. 375-385
Closed Access | Times Cited: 137
The immune microenvironment of breast ductal carcinoma in situ
Elizabeth D. Thompson, Janis M. Taube, Hillary Elwood, et al.
Modern Pathology (2016) Vol. 29, Iss. 3, pp. 249-258
Open Access | Times Cited: 135
Comparison of tumor‐infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients
Rin Ogiya, Naoki Niikura, Nobue Kumaki, et al.
Cancer Science (2016) Vol. 107, Iss. 12, pp. 1730-1735
Open Access | Times Cited: 128
Epigenetic and Transcriptomic Profiling of Mammary Gland Development and Tumor Models Disclose Regulators of Cell State Plasticity
Christopher Dravis, Chi‐Yeh Chung, Nikki K. Lytle, et al.
Cancer Cell (2018) Vol. 34, Iss. 3, pp. 466-482.e6
Open Access | Times Cited: 125
Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions
Lironne Wein, Peter Savas, Stephen J. Luen, et al.
Frontiers in Oncology (2017) Vol. 7
Open Access | Times Cited: 105
Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art
Cinzia Solinas, Luisa Carbognin, Pushpamali De Silva, et al.
The Breast (2017) Vol. 35, pp. 142-150
Closed Access | Times Cited: 104
Immune Escape during Breast Tumor Progression
Carlos R. Gil Del Alcazar, Maša Alečković, Kornélia Polyák
Cancer Immunology Research (2020) Vol. 8, Iss. 4, pp. 422-427
Open Access | Times Cited: 102
Checkpoint blockade in the treatment of breast cancer: current status and future directions
Lironne Wein, Stephen J. Luen, Peter Savas, et al.
British Journal of Cancer (2018) Vol. 119, Iss. 1, pp. 4-11
Open Access | Times Cited: 100
The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)
Nobumoto Tomioka, Manabu Azuma, Mayuko Ikarashi, et al.
Breast Cancer (2017) Vol. 25, Iss. 1, pp. 34-42
Open Access | Times Cited: 98
Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors
Li Zhu, Jessica L. Narloch, Sayali Onkar, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 83
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
Leisha A. Emens, Sylvia Adams, Ashley Cimino‐Mathews, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 8, pp. e002597-e002597
Open Access | Times Cited: 68
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer
Elisa Agostinetto, Agnese Losurdo, Guilherme Nader Marta, et al.
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 6, pp. 567-591
Open Access | Times Cited: 58
Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges
Xiaoxiao Wang, L. Collet, Mattia Rediti, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 3, pp. 953-953
Open Access | Times Cited: 34
Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes
Hee Jin Lee, Jeong-Ju Lee, In Hye Song, et al.
Breast Cancer Research and Treatment (2015) Vol. 151, Iss. 3, pp. 619-627
Closed Access | Times Cited: 68
Page 1 - Next Page

Scroll to top